Timothy W. Mullett named chair of the Commission on Cancer of the American College of Surgeons

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Cardiothoracic surgeon Timothy W. Mullett, medical director of the Markey Cancer Center Affiliate Network, was named chair of the Commission on Cancer of the American College of Surgeons.

Mullett has been serving as the chair-elect of the CoC for the past year.

Mullett is a surgical oncologist who specializes in the treatment of lung cancer. Although he began his career at the University of Kentucky as a cardiothoracic surgeon treating heart issues, he soon shifted his professional focus to treating lung cancer. Today, he is a co-leader and principal investigator of the Kentucky LEADS Collaborative to improve lung cancer survival.

In addition to his work in lung cancer research, Mullett serves as the chair of UK’s cancer committee and the medical director of the Markey Cancer Center Research Network, a collaborative network that conducts high-priority trials, including therapeutic oncology trials and interventional and non-interventional studies for community centers.

In his role as chair, Mullett will serve as the spokesperson for oncology issues addressed by the organization, identify priorities for the CoC and National Cancer Database.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login